27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
UBS checked in with healthcare provider Centene Corp (NYSE: CNC) management this week and reported no fundamental changes on its outlook despite share weakness.
Centene is approaching the end of its talks with California regulators regarding potential changes in its off-exchange PPO plan in the state, according to UBS. Centene is looking for a 23 percent rate increase along with benefit design changes for 2017.
California has informed Centene management that the state is comfortable approving certain of the requested benefit design changes. If the rate hike were approved, it would reduce losses by 50 percent. The decision is expected to be made at the end of the month.
Last week, Pennsylvania picked Centene alongside two other private MCO's (a contract worth approximately $7 billion) to manage long-term care in the state for over 420,000 low-income individuals.
UBS has a Buy rating on Centene with a 12-month price target of $80.
Centene traded up 2.6 percent to $67.04.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!